TradeUSAsignals RecommendationsDXCM - Short (5% of your portfolio) - Order filled @ 75.7
We have a downtrend dominated by bargain hunters, with a strong break below the lower boundary of the channel
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.24 EUR
556.60 M EUR
3.90 B EUR
386.79 M
About DexCom, Inc.
Sector
Industry
CEO
Kevin Ronald Sayer
Website
Headquarters
San Diego
Founded
1999
ISIN
US2521311074
FIGI
BBG00PH0BZY8
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.
Related stocks
Breakout coming soon Price is ready to break 90$ resistance (light blu line) !
A large GAP is also waiting to be filled above 90$
I think everything is ready to push price up
DXCM DexCom Options Ahead of EarningsAnalyzing the options chain and the chart patterns of DXCM DexCom prior to the earnings report this week,
I would consider purchasing the 90usd strike price Calls with
an expiration date of 2025-2-21,
for a premium of approximately $1.65.
If these options prove to be profitable prior to the earnings
BreakoutPrice finally breaking out of green channel up
A lot of GAPs are waiting to be filled upward
$DXCM - Breaking Out Now! 46% Upside!Chart #20/ 40: NASDAQ:DXCM 🏥
-Symmetrical Triangle Breakout with breakdown Retest
-H5 Indicator is Green
-Williams Consolidation Box Support Created
-AVP Shelf to launch off with Massive VOLUME GAP
🎯$110📏 $91 ⏳ Before APR2025
NFA
DXCM LongLong on Diabetes. Diabetes will only get worse as we continue to eat garbage everyday. Fib level.
DXCM Long Swing Analysis
DXCM offers a compelling swing trade setup, with a strong base forming over the past 4 months around a critical support zone of $74–$68. Following a drop on July 2024 earnings, the stock remains resilient, supported by robust revenue figures and, in my view, a superior CGM product tha
Dexcom Inc. 1. Company Overview and Industry Growth Potential
Dexcom Inc. is a prominent player in the medical technology industry, focusing on continuous glucose monitoring (CGM) systems primarily used by individuals with diabetes. The company's flagship product line, the Dexcom G Series, offers real-time glu
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
DXCM5813816
DexCom, Inc. 0.375% 15-MAY-2028Yield to maturity
—
Maturity date
May 15, 2028
DXCM5195221
DexCom, Inc. 0.25% 15-NOV-2025Yield to maturity
—
Maturity date
Nov 15, 2025
See all DC4 bonds
Frequently Asked Questions
The current price of DC4 is 65.31 EUR — it has increased by 2.25% in the past 24 hours. Watch DexCom, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange DexCom, Inc. stocks are traded under the ticker DC4.
DC4 stock has fallen by −0.43% compared to the previous week, the month change is a −4.67% fall, over the last year DexCom, Inc. has showed a 5.10% increase.
We've gathered analysts' opinions on DexCom, Inc. future price: according to them, DC4 price has a max estimate of 105.11 EUR and a min estimate of 77.96 EUR. Watch DC4 chart and read a more detailed DexCom, Inc. stock forecast: see what analysts think of DexCom, Inc. and suggest that you do with its stocks.
DC4 stock is 3.99% volatile and has beta coefficient of 1.21. Track DexCom, Inc. stock price on the chart and check out the list of the most volatile stocks — is DexCom, Inc. there?
Today DexCom, Inc. has the market capitalization of 25.04 B, it has decreased by −1.36% over the last week.
Yes, you can track DexCom, Inc. financials in yearly and quarterly reports right on TradingView.
DexCom, Inc. is going to release the next earnings report on Oct 23, 2025. Keep track of upcoming events with our Earnings Calendar.
DC4 earnings for the last quarter are 0.41 EUR per share, whereas the estimation was 0.38 EUR resulting in a 8.21% surprise. The estimated earnings for the next quarter are 0.49 EUR per share. See more details about DexCom, Inc. earnings.
DexCom, Inc. revenue for the last quarter amounts to 982.27 M EUR, despite the estimated figure of 954.68 M EUR. In the next quarter, revenue is expected to reach 1.01 B EUR.
DC4 net income for the last quarter is 152.63 M EUR, while the quarter before that showed 97.43 M EUR of net income which accounts for 56.67% change. Track more DexCom, Inc. financial stats to get the full picture.
No, DC4 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 3, 2025, the company has 10.3 K employees. See our rating of the largest employees — is DexCom, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DexCom, Inc. EBITDA is 783.79 M EUR, and current EBITDA margin is 20.28%. See more stats in DexCom, Inc. financial statements.
Like other stocks, DC4 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DexCom, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DexCom, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DexCom, Inc. stock shows the strong sell signal. See more of DexCom, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.